Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 

Published byOle-Martin Petersen Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation "— Presentation transcript:

1 Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation  Margaret L. Green, Wendy Leisenring, Daniel Stachel, Steven A. Pergam, Brenda M. Sandmaier, Anna Wald, Lawrence Corey, Michael Boeckh  Biology of Blood and Marrow Transplantation  Volume 18, Issue 11, Pages (November 2012) DOI: /j.bbmt Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 (A) Cumulative incidence of cytomegalovirus (CMV) reactivation, (B) initiation of preemptive therapy, (C) CMV disease in seropositive recipients (R+) and (D) CMV seropositive donor/CMV seronegative recipient (D+/R−) patients (n = 1,057). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Cumulative incidence of nonrelapse mortality (NRM) by 1 year after hematopoietic cell transplantation (HCT). (A) Cytomegalovirus (CMV) surveillance group (n = 1,057). (B) Donor and recipient CMV serostatus (n = 1,597). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation "

Similar presentations

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.
Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation  Frans M. Verduyn Lunel,

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation  Frans M. Verduyn Lunel,
Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome  Joseph Delano F. Robles, Daniel.

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome  Joseph Delano F. Robles, Daniel.
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Joshua A. Hill, MD, Bryan Mayer, PhD, Hu Xie, MS, Wendy M

Joshua A. Hill, MD, Bryan Mayer, PhD, Hu Xie, MS, Wendy M
Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.
Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients  Steven A. Pergam, Hu Xie, Ravinder Sandhu, Margaret.

Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients  Steven A. Pergam, Hu Xie, Ravinder Sandhu, Margaret.
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:
Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients 

Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients 
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Similar presentations

Ads by Google